Trilipix to stay on market, but FDA panel recommends new study
An FDA advisory panel recommended fenofibric acid (Trilipix, Abbott) still be marketed for use but voted unanimously that Abbott be required to conduct a new study to determine whether a Trilipix-statin combination reduces heart attacks.
An FDA advisory panel recommended fenofibric acid (Trilipix, Abbott) still be marketed for use but voted unanimously that Abbott be required to conduct a new study to determine whether a Trilipix-statin combination reduces heart attacks.
Trilipix is a fibrate drug approved by FDA in 2008 to lower LDL cholesterol and triglycerides and increase HDL cholesterol. The review and recommendation followed the results of a study released in March 2010 of a similar Abbott drug, TriCor, that showed that diabetic patients taking a fenobibric acid-simvastatin (Zocor) combination had as many heart attacks as those taking simvastatin alone (2.24% vs 2.41% per year, HR 0.92, P=.32).
Based on the review, 9 of 13 panelists voted that the drug's label should keep the combination as an approved use. Six voted that the label should be updated; while 3 said the label did not need to change.
On the requirement to conduct a new study, Wells Fargo Analyst Larry Biegelsen was quoted in a recent Associated Press article, stating that, if required, it could cost Abbott $100 million to conduct and would be a "modest negative,” and that a change in the drug's label would have virtually no effect on the company’s results.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
